Biogen's ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 25 2025
0mins
Source: NASDAQ.COM
Marketing Authorization for ZURZUVAE: Biogen Inc. announced that the European Medicines Agency's Committee has recommended marketing authorization for ZURZUVAE, a treatment for postpartum depression in adults, based on positive results from the SKYLARK study.
Next Steps and Significance: The recommendation will be reviewed by the European Commission, with a final decision expected in Q3 2025; if approved, ZURZUVAE will be the first EU-authorized treatment specifically for postpartum depression.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 184.00 USD with a low forecast of 149.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
12 Buy
10 Hold
0 Sell
Moderate Buy
Current: 168.570
Low
149.00
Averages
184.00
High
250.00
Current: 168.570
Low
149.00
Averages
184.00
High
250.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
